See more : Entyr Limited (ETR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Emerald Health Therapeutics, Inc. (EMHTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Emerald Health Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- HCM Acquisition Corp (HCMAW) Income Statement Analysis – Financial Results
- Advance Auto Parts, Inc. (0H9G.L) Income Statement Analysis – Financial Results
- Shinih Enterprise Co., Ltd. (9944.TW) Income Statement Analysis – Financial Results
- Sustainable Power & Infrastructure Split Corp. (PWI.TO) Income Statement Analysis – Financial Results
- BKM Industries Limited (BKMINDST.BO) Income Statement Analysis – Financial Results
Emerald Health Therapeutics, Inc. (EMHTF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://emeraldhealth.ca
About Emerald Health Therapeutics, Inc.
Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production, distribution, and sale of recreational and medical cannabis in Canada. It offers dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products under the SYNC Wellness, fuse, Emerald, and Souvenir brands. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada. As of November 10, 2022, Emerald Health Therapeutics, Inc. operates as a subsidiary of Skye Bioscience, Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.68M | 11.74M | 20.32M | 1.95M | 937.65K | 253.32K | 31.29K | 0.00 | 117.55K | 233.74K | 46.57K | 0.00 | 0.00 |
| Cost of Revenue | 16.14M | 21.41M | 34.79M | 5.05M | 1.22M | 603.27K | 203.80K | 0.00 | 53.18K | 94.17K | 17.25K | 0.00 | 0.00 |
| Gross Profit | -6.46M | -9.67M | -14.47M | -3.10M | -285.52K | -349.95K | -172.51K | 0.00 | 64.37K | 139.57K | 29.32K | 0.00 | 0.00 |
| Gross Profit Ratio | -66.72% | -82.37% | -71.21% | -159.06% | -30.45% | -138.14% | -551.31% | 0.00% | 54.76% | 59.71% | 62.96% | 0.00% | 0.00% |
| Research & Development | 1.73M | 1.57M | 4.28M | 801.35K | 207.50K | 301.53K | 162.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.92M | 12.44M | 26.04M | 21.49M | 7.89M | 1.90M | 2.76M | 1.88M | 94.87K | 77.47K | 60.25K | 26.42K | 63.62K |
| Selling & Marketing | 2.37M | 1.56M | 4.37M | 11.33M | 428.54K | 271.12K | 360.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.29M | 14.00M | 30.41M | 32.83M | 8.32M | 2.17M | 3.12M | 1.88M | 94.87K | 77.47K | 60.25K | 26.42K | 63.62K |
| Other Expenses | 1.25M | 1.76M | 1.85M | 618.44K | 282.45K | 116.35K | 46.41K | 20.19K | 57.97K | 70.02K | 14.30K | 0.00 | 0.00 |
| Operating Expenses | 14.27M | 17.33M | 36.54M | 34.25M | 8.81M | 2.59M | 3.32M | 1.90M | 152.84K | 147.49K | 74.55K | 26.42K | 63.62K |
| Cost & Expenses | 30.41M | 38.74M | 71.33M | 39.29M | 10.03M | 3.19M | 3.53M | 1.90M | 206.01K | 241.66K | 91.80K | 26.42K | 63.62K |
| Interest Income | 298.00K | 1.28M | 952.88K | 1.19M | 161.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 451.00 | 1.90K |
| Interest Expense | 700.00K | 4.97M | 765.64K | 218.60K | 0.00 | 39.68K | 0.00 | 0.00 | 52.08K | 63.04K | 13.00K | 154.00 | 0.00 |
| Depreciation & Amortization | 2.85M | 4.82M | 6.43M | 3.45M | 282.45K | 116.35K | 46.41K | 20.19K | 61.66K | 70.02K | 14.30K | 605.00 | 1.90K |
| EBITDA | -35.61M | -32.96M | -105.81M | -26.93M | -8.45M | -2.78M | -3.45M | -2.62M | -30.50K | 62.10K | -30.93K | -25.97K | -61.83K |
| EBITDA Ratio | -367.94% | -280.78% | -520.74% | -1,382.37% | -901.12% | -1,099.19% | -11,028.29% | 0.00% | -25.94% | 26.57% | -66.41% | 0.00% | 0.00% |
| Operating Income | -38.47M | -37.78M | -112.24M | -30.38M | -8.73M | -2.90M | -3.50M | -2.65M | -92.16K | -7.93K | -45.23K | -26.58K | -63.73K |
| Operating Income Ratio | -397.43% | -321.83% | -552.38% | -1,559.31% | -931.24% | -1,145.12% | -11,176.60% | 0.00% | -78.40% | -3.39% | -97.11% | 0.00% | 0.00% |
| Total Other Income/Expenses | -700.00K | -5.56M | -164.02M | -625.12K | -109.99K | -39.68K | 0.00 | 0.00 | -52.08K | -63.04K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -39.17M | -43.34M | -113.01M | -31.01M | -8.84M | -2.94M | -3.50M | -2.65M | -144.24K | -70.97K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -404.66% | -369.19% | -556.15% | -1,591.39% | -942.97% | -1,160.78% | -11,176.60% | 0.00% | -122.70% | -30.36% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 700.00K | 196.00K | -1.10M | -23.61K | -109.99K | 39.68K | 0.00 | 0.00 | 52.08K | 63.04K | 13.00K | -605.00 | -1.90K |
| Net Income | -39.87M | -43.54M | -111.91M | -30.98M | -8.73M | -2.98M | -3.50M | -2.65M | -196.32K | -134.01K | -58.22K | -25.97K | -61.83K |
| Net Income Ratio | -411.89% | -370.86% | -550.74% | -1,590.18% | -931.24% | -1,176.44% | -11,176.60% | 0.00% | -167.01% | -57.33% | -125.02% | 0.00% | 0.00% |
| EPS | -0.21 | -0.23 | -0.76 | -0.22 | -0.10 | -0.05 | -0.08 | -0.07 | -0.10 | -0.07 | -0.03 | -0.05 | -0.21 |
| EPS Diluted | -0.21 | -0.23 | -0.76 | -0.22 | -0.10 | -0.05 | -0.08 | -0.07 | -0.10 | -0.07 | -0.03 | -0.05 | -0.21 |
| Weighted Avg Shares Out | 193.21M | 193.21M | 147.96M | 141.44M | 88.45M | 54.26M | 46.07M | 37.08M | 2.01M | 2.01M | 2.00M | 487.20K | 298.60K |
| Weighted Avg Shares Out (Dil) | 193.21M | 193.21M | 147.96M | 141.44M | 88.45M | 54.26M | 46.07M | 37.08M | 2.01M | 2.01M | 2.00M | 487.20K | 298.60K |
9 Penny Stocks to Buy If You Can Stomach Risk
Penny stocks are wildly dangerous and not meant for risk-averse investors. Still, if you want to play, here are some ideas.
Emerald Health Therapeutics Settles Outstanding Amounts
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it has settled all outstanding amounts owing to the original vendors (the "Vendors") in connection with Emerald's 2018 acquisition...
Emerald Health Therapeutics' Partner STENOCARE Makes First Delivery of Medical Cannabis Oil to Swedish Patients
Vancouver, British Columbia--(Newsfile Corp. - December 29, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that its partner, STENOCARE A/S, completed its first shipment and delivery of Emerald medical cannabis oil to patients in Sweden....
2 Pot Stocks to Sell Before 2021
You'll have better prospects for success by freeing up cash to invest in other stocks.
Emerald Health Therapeutics Introduces High Potency SYNC(TM) 100 CBD Oil
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has launched and made its first shipment of its new SYNC™ 100 CBD oil to the province of Saskatchewan. Shipments to Alberta...
Emerald Health Therapeutics Terminates Agreement for Sale of Quebec Cannabis Business
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it has terminated its share purchase agreement dated July 30, 2020 (the "Agreement") with Quinto Resources Inc. ("Quinto") in...
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q3 2020 Results - Earnings Call Transcript
Emerald Health Therapeutics, Inc. (EMHTF) CEO Riaz Bandali on Q3 2020 Results - Earnings Call Transcript
Emerald Health Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Emerald hosting conference call today, December 1st, at 10:30 am ETVancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has released its financial results for the three and nine months ended...
Emerald Health Therapeutics Completes Sale of Pure Sunfarms Interest & Achieves Pivotal Milestone in Transforming its Business
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") has completed the previously disclosed sale of its 41.3% interest in Pure Sunfarms Corp. ("PSF") to Village Farms International, Inc....
Source: https://incomestatements.info
Category: Stock Reports